91
Participants
Start Date
September 30, 2019
Primary Completion Date
June 30, 2020
Study Completion Date
June 30, 2020
Neflamapimod
Double-Blind, Placebo-Controlled
New York Presbyterian Hospital - Columbia University Medical Center, New York
University of Rochester, Rochester
Thomas Jefferson University, Philadelphia
University of Virginia, Charlottesville
National Clinical Research, Inc., Richmond
University of North Carolina, Chapel Hill
Elite Clinical Research, Miami
The Ohio State University, Columbus
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
Mayo Clinic, Rochester
University of Kansas Medical Center, Kansas City
University of Colorado, Aurora
Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas
Pacific Neuroscience Institute, Santa Monica
University of California San Diego (UCSD), La Jolla
Summit Research Network, Portland
Oregon Health & Science University, Portland
Northwest Clinical Research Center, Bellevue
University of Washington, Seattle
Inland Northwest Research, Spokane
Massachusetts General Hospital, Charlestown
Brain Research Center, 's-Hertogenbosch
Brain Research Center, Amsterdam
Lead Sponsor
Collaborators (1)
Worldwide Clinical Trials
OTHER
EIP Pharma Inc
INDUSTRY